Marion Merrell Dow v. Geneva Generics
Lawsuit filed March 3 "by MMD claims that Geneva is infringing one of its patents for Seldane (terfenadine). MMD claims that Geneva's ANDA for a carboxylic acid metabolite of terfenadine, submitted to FDA on Feb. 8, infringes on its patent 4,254,129, Originally issued in 1981. Geneva challenged the patent in a Feb. 8 letter to MMD. MMD claims that the basic Seldane patent, 3,878,217, which expires April 15, 1994, is not the patent pertaining to the metabolite. Geneva says it plans to file a counterclaim shortly. The suit is filed in Denver federal court
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth